HDAC9 and mature T-cell and NK-cell non-Hodgkin lymphoma: Romidepsin (FK228) is a class I HDAC inhibitor [108] and was the second FDA-approved HDAC inhibitor for the treatment of refractory CTCL and PTCL [109].